Illumina, Inc. (NASDAQ:ILMN) Receives $137.55 Average Target Price from Analysts

Illumina, Inc. (NASDAQ:ILMN) has been assigned an average rating of “Hold” from the twenty-one research firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, ten have given a hold recommendation, nine have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $137.55.

ILMN has been the subject of several research analyst reports. Stephens reiterated an “overweight” rating and set a $156.00 target price on shares of Illumina in a research note on Tuesday, March 11th. Hsbc Global Res lowered shares of Illumina from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 28th. HSBC downgraded shares of Illumina from a “buy” rating to a “hold” rating and set a $100.00 target price for the company. in a report on Friday, February 28th. Morgan Stanley lowered their price target on shares of Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 11th. Finally, Robert W. Baird reduced their price objective on Illumina from $127.00 to $90.00 and set a “neutral” rating for the company in a report on Wednesday, March 5th.

Hedge Funds Weigh In On Illumina

A number of institutional investors have recently modified their holdings of the business. Golden State Wealth Management LLC acquired a new position in Illumina during the fourth quarter worth about $32,000. Versant Capital Management Inc lifted its stake in Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after purchasing an additional 146 shares during the last quarter. Fourth Dimension Wealth LLC bought a new stake in shares of Illumina during the fourth quarter worth $40,000. Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of Illumina during the fourth quarter worth $45,000. Finally, Assetmark Inc. lifted its stake in shares of Illumina by 954.8% in the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock valued at $44,000 after acquiring an additional 296 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Price Performance

Shares of ILMN opened at $77.88 on Wednesday. The company has a market cap of $12.33 billion, a price-to-earnings ratio of -10.14, a PEG ratio of 1.60 and a beta of 1.38. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The company’s fifty day simple moving average is $80.07 and its 200 day simple moving average is $115.86. Illumina has a 1-year low of $68.70 and a 1-year high of $156.66.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. On average, research analysts forecast that Illumina will post 4.51 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.